Methotrexate use and liver disease - a causal relationship?

Abstract

For patients with moderate-to-severe psoriasis, current guidelines recommend systemic treatment to achieve adequate disease control.1 Although more than 90 percent of dermatologists are aware of the national treatment guidelines for psoriasis2, less than 50 percent of patients with moderate-to-severe psoriasis receive systemic treatment3. A survey of dermatologists from Europe and Canada recently identified safety concerns as an important barrier to the use of methotrexate for psoriasis treatment.4